Fagron launches excipients line DiluCap - making capsule formulation easier and more reliable

Fagron, the leading global player in pharmaceutical compounding, launches DiluCap, a new line of six excipients for compounding pharmacies allowing for easier and faster capsule formulation.

Choosing the right excipient is paramount for the adequate clinical performance of a robust dosage form. This choice must be based on technical parameters of both the Active Pharmaceutical Ingredient (API) and the functionality of the dosage form itself. Therefore, science must be at the backbone of such process. Fagron’s Dilucap comes with a patented algorithm that assists health care professionals in primary compounding facilities, pharmacies, and hospital pharmacies with choosing the best excipient for the intended medicinal preparation based on a scientifically rigid decision process. Dilucap facilitates the prevention of quality and safety differences between medicinal products compounded in pharmacies to meet specific patient’s needs and those prepared on an industrial scale in line with the EU Resolution CM/Res (2016)1.

Fagron’s DiluCap is a line of excipients specially developed to support compounding pharmacy professionals to prepare every capsule formulation with ease and trust in its final characteristics. All excipients were developed following scientific criteria and were extensively tested to prove their performance.

Anderson Ferreira, New Product Development Scientist Pharma R&D at Fagron comments: “With DiluCap, the pharmacist has an ideal excipient solution for each specific compounded formulation, considering the desired preparation process optimization, stability, compatibility, and formulation performance. All you need to do is to check the table with the most suitable product indication and choose the best DiluCap excipient”.

For each API, there is a DiluCap excipient

The number of excipients available on the market is significant and selecting the best excipient is complicated: there are more than a thousand different excipients available as individual ingredients for diverse dosage forms. Fagron’s DiluCap line consists of only six excipients using the Biopharmaceutical Classification System (BCS) and has been developed to help the performance of all types of APIs for oral use on solid dosage forms.

Features and benefits of Fagron’s DiluCap include:

• Avoidance of segregation between the API and the other formulation components
• Preservation of API stability
• Dose accuracy
• Modulation of the solubility and bioavailability of the API
• Absence of allergens such as lactose, gluten, soy, and others
• No need for other adjuvants
• Reduction of process time and the number of items in stock
• Batch-to-batch reproducibility

DiluCap is only available at Fagron. To check out the complete product line and technical material, please visit fagron.com/brands/dilucap/

References:

Ferreira AO, Polonini H. Evaluation of the Physical-chemical Characteristics and Biopharmaceutical Performance of Dilu-Cap: A Complete Line of Excipients for Hard-shell Capsules. Int J Pharm Compd. 2022 Jul-Aug;26(4):283-291. PMID: 35820133.

Further information

Hudson Polonini

Global Innovation Project Manager

Phone: +31622514018

Email: Hudson.Polonini@fagron.com

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.